RU2007102288A - Новые тиазольные ингибиторы фруктозо-1,6-бисфосфатазы - Google Patents
Новые тиазольные ингибиторы фруктозо-1,6-бисфосфатазы Download PDFInfo
- Publication number
- RU2007102288A RU2007102288A RU2007102288/04A RU2007102288A RU2007102288A RU 2007102288 A RU2007102288 A RU 2007102288A RU 2007102288/04 A RU2007102288/04 A RU 2007102288/04A RU 2007102288 A RU2007102288 A RU 2007102288A RU 2007102288 A RU2007102288 A RU 2007102288A
- Authority
- RU
- Russia
- Prior art keywords
- group
- compound according
- attached
- nhch
- case
- Prior art date
Links
- 102000012195 Fructose-1,6-bisphosphatases Human genes 0.000 title claims 6
- 108010017464 Fructose-Bisphosphatase Proteins 0.000 title claims 6
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- -1 3-ethyl-3-pentyl Chemical group 0.000 claims 54
- 150000001875 compounds Chemical class 0.000 claims 51
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 20
- 125000000217 alkyl group Chemical group 0.000 claims 15
- 125000003118 aryl group Chemical group 0.000 claims 14
- 125000004429 atom Chemical group 0.000 claims 13
- 150000003839 salts Chemical class 0.000 claims 12
- 125000003710 aryl alkyl group Chemical group 0.000 claims 9
- 125000005842 heteroatom Chemical group 0.000 claims 8
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims 7
- 125000001072 heteroaryl group Chemical group 0.000 claims 7
- 238000000034 method Methods 0.000 claims 7
- 239000000651 prodrug Substances 0.000 claims 7
- 229940002612 prodrug Drugs 0.000 claims 7
- 125000003107 substituted aryl group Chemical group 0.000 claims 7
- 125000004122 cyclic group Chemical group 0.000 claims 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 6
- 125000006637 cyclobutyl carbonyl group Chemical group 0.000 claims 5
- 241001465754 Metazoa Species 0.000 claims 4
- 125000004432 carbon atom Chemical group C* 0.000 claims 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 206010012601 diabetes mellitus Diseases 0.000 claims 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 3
- 229910052698 phosphorus Inorganic materials 0.000 claims 3
- 239000011574 phosphorus Substances 0.000 claims 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 3
- 125000004398 2-methyl-2-butyl group Chemical group CC(C)(CC)* 0.000 claims 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 2
- 125000004423 acyloxy group Chemical group 0.000 claims 2
- 125000005194 alkoxycarbonyloxy group Chemical group 0.000 claims 2
- 125000005200 aryloxy carbonyloxy group Chemical group 0.000 claims 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000008103 glucose Substances 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 2
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000006239 protecting group Chemical group 0.000 claims 2
- 125000004338 2,2,3-trimethylbutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])* 0.000 claims 1
- GTEZSHJBMRWRIG-UHFFFAOYSA-N 2-amino-3-[4-(naphthalene-2-carbonyloxy)phenyl]propanoic acid Chemical group C1=CC(CC(N)C(O)=O)=CC=C1OC(=O)C1=CC=C(C=CC=C2)C2=C1 GTEZSHJBMRWRIG-UHFFFAOYSA-N 0.000 claims 1
- 125000003541 2-chlorobenzoyl group Chemical group ClC1=C(C(=O)*)C=CC=C1 0.000 claims 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 claims 1
- 125000004921 3-methyl-3-pentyl group Chemical group CC(CC)(CC)* 0.000 claims 1
- 125000001999 4-Methoxybenzoyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C(*)=O 0.000 claims 1
- 125000000242 4-chlorobenzoyl group Chemical group ClC1=CC=C(C(=O)*)C=C1 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- 241000046053 Betta Species 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 125000005041 acyloxyalkyl group Chemical group 0.000 claims 1
- 125000005205 alkoxycarbonyloxyalkyl group Chemical group 0.000 claims 1
- 125000002877 alkyl aryl group Chemical group 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000013256 coordination polymer Substances 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000006165 cyclic alkyl group Chemical group 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000006638 cyclopentyl carbonyl group Chemical group 0.000 claims 1
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 125000000547 substituted alkyl group Chemical group 0.000 claims 1
- 125000005750 substituted cyclic group Chemical group 0.000 claims 1
- 229940095064 tartrate Drugs 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/99—Enzyme inactivation by chemical treatment
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60251804P | 2004-08-18 | 2004-08-18 | |
| US60/602,518 | 2004-08-18 | ||
| US66213805P | 2005-03-15 | 2005-03-15 | |
| US60/662,138 | 2005-03-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2007102288A true RU2007102288A (ru) | 2008-09-27 |
Family
ID=35968113
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2007102288/04A RU2007102288A (ru) | 2004-08-18 | 2005-08-18 | Новые тиазольные ингибиторы фруктозо-1,6-бисфосфатазы |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20070225259A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1778250A2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2008510018A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20070053764A (cg-RX-API-DMAC7.html) |
| CN (1) | CN101005847A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2005277479A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0514372A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2577373A1 (cg-RX-API-DMAC7.html) |
| RU (1) | RU2007102288A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2006023515A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6284748B1 (en) | 1997-03-07 | 2001-09-04 | Metabasis Therapeutics, Inc. | Purine inhibitors of fructose 1,6-bisphosphatase |
| KR100818845B1 (ko) | 1998-09-09 | 2008-04-01 | 메타베이시스 테라퓨틱스, 인크. | 신규한 프럭토스 1,6-비스포스파타제의 헤테로방향족 억제제 |
| CN1516705A (zh) | 2000-03-08 | 2004-07-28 | ֢�����ƹ�˾ | 新的芳基果糖-1,6-二磷酸酶抑制剂 |
| US7563774B2 (en) | 2000-06-29 | 2009-07-21 | Metabasis Therapeutics, Inc. | Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes |
| CA2666193A1 (en) | 2006-08-08 | 2008-02-14 | Sanofi-Aventis | Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use |
| DE102007005045B4 (de) | 2007-01-26 | 2008-12-18 | Sanofi-Aventis | Phenothiazin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| WO2009012039A2 (en) * | 2007-07-13 | 2009-01-22 | Metabasis Therapeutics Inc. | Crystalline polymorphs |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| EP2058308A1 (fr) | 2007-11-12 | 2009-05-13 | Merck Sante | Dérivés de benzimidazoledihydrothiadiazinone comme inhibiteurs de fructose-1,6-biphosphatase et compositions pharmaceutiques les contenant. |
| AR072707A1 (es) | 2008-07-09 | 2010-09-15 | Sanofi Aventis | Compuestos heterociclicos, procesos para su preparacion, medicamentos que comprenden estos compuestos y el uso de los mismos |
| WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
| AU2010288523A1 (en) | 2009-08-26 | 2012-03-15 | Sanofi | Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8933024B2 (en) | 2010-06-18 | 2015-01-13 | Sanofi | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| WO2012120057A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2683702B1 (de) | 2011-03-08 | 2014-12-24 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2683701B1 (de) | 2011-03-08 | 2014-12-24 | Sanofi | Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| US8828994B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| EP2683699B1 (de) | 2011-03-08 | 2015-06-24 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| US8828995B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| EP2766349B1 (de) | 2011-03-08 | 2016-06-01 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2683700B1 (de) | 2011-03-08 | 2015-02-18 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| US8809325B2 (en) | 2011-03-08 | 2014-08-19 | Sanofi | Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| US8859098B2 (en) * | 2012-05-18 | 2014-10-14 | Lord Corporation | Acrylic adhesion promoters |
| CN110156838A (zh) * | 2013-05-14 | 2019-08-23 | 北京美倍他药物研究有限公司 | 磷酸/膦酸衍生物及其医药用途 |
| CN108289899A (zh) * | 2015-09-22 | 2018-07-17 | 维京治疗公司 | 采用葡萄糖生成的抑制剂的联合疗法 |
| CN109071577A (zh) * | 2016-04-22 | 2018-12-21 | 症变治疗公司 | 甲状腺激素受体激动剂及其用途 |
| CN109535298B (zh) * | 2017-09-22 | 2021-04-13 | 中国石油化工股份有限公司 | 前过渡金属化合物及制备方法和烯烃聚合用催化剂组合物及应用和制备烯烃聚合物的方法 |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3454635A (en) * | 1965-07-27 | 1969-07-08 | Hoechst Ag | Benzenesulfonyl-ureas and process for their manufacture |
| US3551422A (en) * | 1968-03-27 | 1970-12-29 | Stevens & Co Inc J P | N-(oxymethyl) derivatives of phosphonopolyamino-s-triazines |
| US3822296A (en) * | 1969-01-23 | 1974-07-02 | Merck & Co Inc | 1-trifluoromethyl-1,2-epoxyethyl-1-phosphonic acid and its salts |
| US3657282A (en) * | 1969-01-23 | 1972-04-18 | Merck & Co Inc | Carboxyepoxyethyl-1-phosphonic acid and derivatives |
| GB1428137A (en) * | 1972-09-27 | 1976-03-17 | Ici Ltd | Prostanoic acid derivatives |
| US4000305A (en) * | 1972-09-27 | 1976-12-28 | Imperial Chemical Industries Limited | 15-, 16- AND 17-Indolyl or indolinyl nor prostanoic acid derivatives |
| US4092323A (en) * | 1975-09-16 | 1978-05-30 | Imperial Chemical Industries Limited | Hydrazine derivatives of pyridyl-ketones |
| GB1516347A (en) * | 1975-09-16 | 1978-07-05 | Ici Ltd | Process for the preparation of alkylphosphonate esters |
| DE2855659A1 (de) * | 1978-12-22 | 1980-07-03 | Bayer Ag | Benzimidazolyl-2-alkan-phosphonsaeuren |
| FR2531088B1 (fr) * | 1982-07-29 | 1987-08-28 | Sanofi Sa | Produits anti-inflammatoires derives de l'acide methylenediphosphonique et leur procede de preparation |
| DK277484A (da) * | 1983-06-23 | 1984-12-24 | Hoffmann La Roche | Thiazolidinderivater |
| DE3776880D1 (de) * | 1986-11-21 | 1992-04-02 | Ciba Geigy Ag | Neue substituierte alkandiphosphonsaeuren. |
| US4728739A (en) * | 1987-06-15 | 1988-03-01 | American Home Products Corporation | Hypoglycemic thiazolidinediones |
| US4791125A (en) * | 1987-12-02 | 1988-12-13 | Pfizer Inc. | Thiazolidinediones as hypoglycemic and anti-atherosclerosis agents |
| US4968790A (en) * | 1988-08-12 | 1990-11-06 | American Cyanamid Company | Antidiabetic phosphates |
| US5658889A (en) * | 1989-01-24 | 1997-08-19 | Gensia Pharmaceuticals, Inc. | Method and compounds for aica riboside delivery and for lowering blood glucose |
| MX21452A (es) * | 1989-07-07 | 1994-01-31 | Ciba Geigy Ag | Preparaciones farmaceuticas que se administran en forma topica. |
| EP0438375B1 (de) * | 1990-01-18 | 1995-12-27 | Ciba-Geigy Ag | Phoshponsäure- und Thionophosphonsäure-Derivate |
| US5116919A (en) * | 1990-12-05 | 1992-05-26 | E. I. Du Pont De Nemours And Company | Process for increasing the relative viscosity of polyamides with reduced thermal degradation |
| JP3053490B2 (ja) * | 1991-02-25 | 2000-06-19 | 杏林製薬株式会社 | チアゾリジン−２，４−ジオン誘導体とその塩及び製造法 |
| US5142000A (en) * | 1991-08-28 | 1992-08-25 | E. I. Du Pont De Nemours And Company | Process for increasing polyamide molecular weight with organophosphonic acid or ester catalysts in the presence of alumina-containing titanium dioxide |
| US5302586A (en) * | 1991-12-19 | 1994-04-12 | G. D. Searle & Co. | Phosphonomethyl-imidazo[1,2-a]pyrimidine-2-carboxylic acid compounds for treatment of neurotoxic injury |
| US5731299A (en) * | 1992-05-29 | 1998-03-24 | The Procter & Gamble Company | Phosphonosulfonate compounds, pharmaceutical compositions, and methods for treating abnormal calcium and phosphate metabolism |
| US5236941A (en) * | 1992-06-30 | 1993-08-17 | American Home Products Corporation | 5-(2-hydroxy-1-arylethylidene)- and 5-(2-oxo-1-arylethylidene)-2,4-thiazolidinediones and derivatives thereof |
| JP2789134B2 (ja) * | 1992-09-28 | 1998-08-20 | ファイザー・インク． | 糖尿病の合併症を制御する置換ピリミジン類 |
| US5478853A (en) * | 1992-10-12 | 1995-12-26 | Adir Et Compagnie | Thazolidinedione compounds |
| DE4303648A1 (de) * | 1993-02-09 | 1994-08-11 | Basf Ag | Verwendung von Aminovinylphosphonsäureestern als Lichtschutzmittel und Stabilisatoren für organisches Material |
| EP0632048B1 (en) * | 1993-06-29 | 2001-03-21 | Mitsubishi Chemical Corporation | Phosphonate-nucleotide ester derivatives |
| US5478852C1 (en) * | 1993-09-15 | 2001-03-13 | Sankyo Co | Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus |
| US5798340A (en) * | 1993-09-17 | 1998-08-25 | Gilead Sciences, Inc. | Nucleotide analogs |
| US5728650A (en) * | 1993-10-07 | 1998-03-17 | Zeneca Limited | Herbicidal aza bisphosphonic acids and compositions containing the same |
| US5532256A (en) * | 1994-05-18 | 1996-07-02 | American Home Products Corporation | New azolidinediones and thiadiazolidinediones as antihyperglycemic agents |
| US5468762A (en) * | 1994-05-18 | 1995-11-21 | American Home Products Corporation | Azolidinediones as antihyperglycemic agents |
| US5925656A (en) * | 1995-04-10 | 1999-07-20 | Dr. Reddy's Research Foundation | Compounds having antidiabetic, hypolipidemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them |
| US6001862A (en) * | 1995-06-02 | 1999-12-14 | Kyorin Pharameuticals Co., Ltd. | N-benzyldioxothiazolidylbenzamide derivatives and processes for preparing the same |
| JP3144624B2 (ja) * | 1995-06-02 | 2001-03-12 | 杏林製薬株式会社 | Ｎ−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法 |
| US6147101A (en) * | 1995-06-02 | 2000-11-14 | Kyorin Pharmaceutical Co., Ltd. | N-benzyldioxothiazolidylbenzamide derivatives and process for producing the same |
| CA2204616C (en) * | 1995-09-18 | 2002-12-17 | Ranjan Mukherjee | Ppar gamma antagonists for treating obesity |
| WO1997024360A1 (fr) * | 1995-12-27 | 1997-07-10 | Otsuka Pharmaceutical Factory, Inc. | Derives de diester d'acide phosphonique |
| ZA981936B (en) * | 1997-03-07 | 1999-09-06 | Metabasis Therapeutics Inc | Novel benzimidazole inhibitors of fructose 1,6-bisphosphatase. |
| US6054587A (en) * | 1997-03-07 | 2000-04-25 | Metabasis Therapeutics, Inc. | Indole and azaindole inhibitors of fructose-1,6-bisphosphatase |
| US6284748B1 (en) * | 1997-03-07 | 2001-09-04 | Metabasis Therapeutics, Inc. | Purine inhibitors of fructose 1,6-bisphosphatase |
| US6008237A (en) * | 1997-12-19 | 1999-12-28 | Merck & Co., Inc. | Arylthiazolidinedione derivatives |
| US6312662B1 (en) * | 1998-03-06 | 2001-11-06 | Metabasis Therapeutics, Inc. | Prodrugs phosphorus-containing compounds |
| KR100818845B1 (ko) * | 1998-09-09 | 2008-04-01 | 메타베이시스 테라퓨틱스, 인크. | 신규한 프럭토스 1,6-비스포스파타제의 헤테로방향족 억제제 |
| US6756360B1 (en) * | 1998-12-24 | 2004-06-29 | Metabasis Therapeutics, Inc. | Combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes |
| NZ512219A (en) * | 1998-12-24 | 2004-12-24 | Metabasis Therapeutics Inc | A combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes |
| US6284672B1 (en) * | 1999-03-02 | 2001-09-04 | Advanced Micro Devices, Inc. | Method of forming a super-shallow amorphous layer in silicon |
| JP2003519154A (ja) * | 1999-12-22 | 2003-06-17 | メタバシス・セラピューティクス・インコーポレイテッド | 新規なビスアミダートホスホネートプロドラッグ |
| CN1516705A (zh) * | 2000-03-08 | 2004-07-28 | ֢�����ƹ�˾ | 新的芳基果糖-1,6-二磷酸酶抑制剂 |
| US7563774B2 (en) * | 2000-06-29 | 2009-07-21 | Metabasis Therapeutics, Inc. | Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes |
| JP2004508297A (ja) * | 2000-07-06 | 2004-03-18 | メタバシス・セラピューティクス・インコーポレイテッド | 糖尿病の治療に有用なｆｂｐアーゼインヒビターおよび抗糖尿病薬の併用剤 |
| JP2004244409A (ja) * | 2002-07-23 | 2004-09-02 | Sankyo Co Ltd | 糖尿病の発症予防薬 |
-
2005
- 2005-08-18 CA CA002577373A patent/CA2577373A1/en not_active Abandoned
- 2005-08-18 BR BRPI0514372-1A patent/BRPI0514372A/pt not_active IP Right Cessation
- 2005-08-18 AU AU2005277479A patent/AU2005277479A1/en not_active Abandoned
- 2005-08-18 US US11/660,169 patent/US20070225259A1/en not_active Abandoned
- 2005-08-18 RU RU2007102288/04A patent/RU2007102288A/ru not_active Application Discontinuation
- 2005-08-18 KR KR1020077006252A patent/KR20070053764A/ko not_active Withdrawn
- 2005-08-18 JP JP2007527958A patent/JP2008510018A/ja active Pending
- 2005-08-18 WO PCT/US2005/029176 patent/WO2006023515A2/en not_active Ceased
- 2005-08-18 EP EP05786716A patent/EP1778250A2/en not_active Withdrawn
- 2005-08-18 CN CNA2005800283014A patent/CN101005847A/zh active Pending
-
2007
- 2007-08-20 US US11/841,840 patent/US20080070868A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20080070868A1 (en) | 2008-03-20 |
| CN101005847A (zh) | 2007-07-25 |
| WO2006023515A2 (en) | 2006-03-02 |
| JP2008510018A (ja) | 2008-04-03 |
| EP1778250A2 (en) | 2007-05-02 |
| CA2577373A1 (en) | 2006-03-02 |
| AU2005277479A1 (en) | 2006-03-02 |
| BRPI0514372A (pt) | 2008-06-10 |
| WO2006023515A3 (en) | 2006-07-13 |
| US20070225259A1 (en) | 2007-09-27 |
| KR20070053764A (ko) | 2007-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2007102288A (ru) | Новые тиазольные ингибиторы фруктозо-1,6-бисфосфатазы | |
| JP2008510018A5 (cg-RX-API-DMAC7.html) | ||
| JP2018515434A5 (cg-RX-API-DMAC7.html) | ||
| RU2015107803A (ru) | Производные дигидроксипиримидинкарбоновой кислоты и их применение в лечении, облегчении или предотвращении вирусного заболевания | |
| JP2005533040A5 (cg-RX-API-DMAC7.html) | ||
| JP5695200B2 (ja) | 複素環アミノベルバミン誘導体、その調製方法及び使用 | |
| DE602004001864T2 (de) | Verbindungen und methoden zur behandlung von proliferativen krankheiten, retinopathie und arthritis | |
| EA021380B1 (ru) | Фуразанобензимидазолы в качестве пролекарств для лечения опухолевых или аутоиммунных заболеваний | |
| RU2012112050A (ru) | Производные дигидроптеридинона, способ их получения и фармацевтическое применение | |
| JP2011507896A5 (cg-RX-API-DMAC7.html) | ||
| RU2013113634A (ru) | Агонисты рецепторов нейротрофинов и их применение в качестве лекарственных средств | |
| JP2018513832A5 (cg-RX-API-DMAC7.html) | ||
| AU2013297476B2 (en) | Compound and pharmaceutical composition for neuropsychological disorder or malignant tumor | |
| JP2019532067A5 (cg-RX-API-DMAC7.html) | ||
| WO2019152536A1 (en) | Inhibitors of the wnt/beta-catenin pathway | |
| JP6184866B2 (ja) | 新規抗がん剤 | |
| RU2010130253A (ru) | Противоопухолевые соединения | |
| KR100916160B1 (ko) | 약제학적 항암 조성물 | |
| RU2008112181A (ru) | Применение конденсированных производных имидазола для лечения заболеваний, опосредованных рецептором ccr3 | |
| EP2064185B1 (en) | 1h-quinolin-4-one compounds, with affinity for the gaba receptor, processes, uses and compositions | |
| CA2800836A1 (en) | Riminophenazines with 2-(heteroaryl)amino substituents and their anti-microbial activity | |
| EP1886996A1 (en) | 1H-Quinolin-4-one compounds, with affinity for the GABA receptor, processes, uses and compositions | |
| HUP0202293A2 (hu) | Új N-benzilpiperazin vegyületek, eljárás előállításukra és a vegyületeket tartalmazó gyógyszerkészítmények | |
| KR20210080378A (ko) | 비만의 치료 | |
| JP2019537613A5 (cg-RX-API-DMAC7.html) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20100701 |